This article may require cleanup to meet Wikipedia's quality standards. The specific problem is: lack of clarity, lots of repetitions and little real information. (June 2016) (Learn how and when to remove this template message)
|Purpose||to determine the correct therapeutic agent for an individual|
Companion diagnostics are co-developed with drugs to aid in selecting or excluding patient groups for treatment with that particular drug on the basis of their biological characteristics that determine responders and non-responders to the therapy.
- "Pfizer Taps Foundation Medicine for CDx Development". Clinical OMICs. 16 January 2018. Retrieved 19 January 2018.
- "Companion Diagnostics" (Page Last Updated 07/14/2016). FDA. Retrieved 26 September 2016.
- Trusheim, MR; Burgess, B; Hu, SX; Long, T; Averbuch, SD; Flynn, AA; Lieftucht, A; Mazumder, A; Milloy, J; Shaw, PM; Swank, D; Wang, J; Berndt, ER; Goodsaid, F; Palmer, MC (31 October 2011). "Quantifying factors for the success of stratified medicine". Nature Reviews. Drug Discovery. 10 (11): 817–33. doi:10.1038/nrd3557. PMID 22037040.
- Kim, Il-Jin (2019-03-06). Companion Diagnostics (CDx) in Precision Medicine. CRC Press. ISBN 978-1-000-00721-3.
- Duffy, MJ; Crown, J (October 2013). "Companion biomarkers: paving the pathway to personalized treatment for cancer". Clinical Chemistry. 59 (10): 1447–56. doi:10.1373/clinchem.2012.200477. PMID 23656699.